TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
Cedric Gegel is an actor, director, and screenwriter based in the New York City area. Watch our candid conversation recorded live on Facebook, where we talk about his EHE diagnosis, treatment, and the impact his diagnosis has had on his life. There's even a sneak peek of his work!
Our Giving Tuesday total is a staggering $183,737 and counting! That's $87,237 in community donations and $96,500 contributed by our Board of Directors.
Let’s keep this momentum going! If you haven’t donated yet, it’s not too late—every dollar makes a difference.
We are overwhelmed with gratitude—not just for your incredible support on #GivingTuesday, but for standing with us every single day.
Stephanie was diagnosed with epithelioid hemangioendothelioma (EHE) in her liver, lungs, spine, ribs, and femur. It's not uncommon for EHE patients to present with metastatic disease. Unlike other cancers, metastatic EHE is not always correlated with a poor prognosis.
We are pleased to announce The EHE Foundation’s 2024 Research Grants Program awards, totaling $307,400, as part of our ongoing commitment to advance our mission to find effective treatments and a cure for EHE. Made possible by 2023 Giving Tuesday gifts, these grants support novel translational research projects that aim to identify and accelerate the […]
Read MoreAt The EHE Foundation, we are committed to finding a cure for epithelioid hemangioendothelioma (EHE), an ultra-rare and potentially aggressive cancer that affects one in a million people. Every contribution helps us advance groundbreaking research, support patients, and foster collaboration among clinicians and researchers worldwide. There are two impactful ways you can support our mission: […]
Read MoreOn September 10, 2024, The EHE Foundation held a virtual meeting of our Scientific & Medical Advisory Board (SMAB). The meeting aimed to welcome new members, review current research projects, and discuss future needs and goals to advance EHE research. The meeting began with a warm welcome to new members of the SMAB: Tom Chen, […]
Read MoreDrs. Silvia Stacchiotti, Sandro Pasquali, and Nadia Zaffaroni (IRCCS – INT, Milan, Italy) and colleagues published their promising findings in Clinical Cancer Research, September 16, 2024. This study, funded in part by The EHE Foundation in partnership with EHE Rare Cancer Charity (UK), aimed to assess the efficacy of sirolimus for the treatment of EHE […]
Read MoreAjay Pobbati, PhD, Brian Rubin, MD, PhD, and colleagues at the Cleveland Clinic published their findings from the study “CDK9 inhibition by dinaciclib is a therapeutic vulnerability in epithelioid hemangioendothelioma” in Clinical Cancer Research, September 13, 2024. This study, funded in part by a grant from The EHE Foundation, provides a strong rationale for investigating […]
Read MoreAs a caregiver, it can be hard to not think about the future and what it may or may not hold. In doing so, it is common for caregivers to experience anticipatory grief, in which we mourn the loss of our loved one while they are still here as well as grieve the future that […]
Read MoreWith enthusiasm and gratitude, The EHE Foundation is proud to celebrate another successful year of the Annual EHE Fun Run & Walk. This event, dedicated to supporting The EHE Foundation’s mission to find treatments and a cure for epithelioid hemangioendothelioma (EHE), always brings our community together in an extraordinary way! With 1387 registrations, our hearts […]
Read MoreThe EHE Foundation invests in novel EHE research yearly through its EHE Research Grants Program. The program officially began in 2021, with only a few applicants interested in EHE research. Today, 10 applicants have submitted proposals in our 2024 grants cycle. Along the way, we have had the good fortune to meet and collaborate with […]
Read MoreOn May 28, 2024, Ikena Oncology announced they are discontinuing the development of IK-930. We share your frustration and disappointment and understand the devastating impact felt by patients. Following this announcement, we met with Ikena to impress upon them the urgency and importance that patients deriving benefits from IK-930 continue to have access to the […]
Read More